120 patents
Page 6 of 6
Utility
Methods for treating hepatitis B infection
12 Oct 20
This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
Martin Koser, Marc Abrams
Filed: 13 Feb 20
Utility
Methods and Compositions for the Specific Inhibition of Kras by Asymmetric Double-stranded Rna
7 Oct 20
This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
Bob D. Brown
Filed: 21 Jun 20
Utility
Compositions and Methods for Inhibiting HMGB1 Expression
23 Sep 20
This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes.
Marc ABRAMS, Girish CHOPDA, Jihye PARK
Filed: 29 Apr 20
Utility
Methods and Compositions for Inhibiting Expression of Ldha
9 Sep 20
This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
Filed: 11 Oct 18
Utility
Beta Catenin Nucleic Acid Inhibitor Molecule
26 Aug 20
Provided herein is a potent, optimized β-catenin nucleic acid inhibitor molecule with a unique pattern of modified nucleotides.
Shanthi GANESH
Filed: 16 Oct 18
Utility
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
24 Aug 20
This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
Bob D. Brown
Filed: 31 Oct 17
Utility
Therapeutic inhibition of lactate dehydrogenase and agents therefor
10 Aug 20
This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek, Cheng Lai
Filed: 14 Mar 19
Utility
Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
22 Jun 20
This invention relates to compounds, compositions, and methods useful for reducing AT3 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 8 May 16
Utility
Compositions and methods for inhibiting HMGB1 expression
8 Jun 20
This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes.
Marc Abrams, Girish Chopda, Jihye Park
Filed: 28 Jun 18
Utility
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
8 Jun 20
This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 22 Oct 18
Utility
Methods for Treating Hepatitis B Infection
3 Jun 20
This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
Martin Koser, Marc Abrams
Filed: 13 Feb 20
Utility
Methods and compositions for the specific inhibition of β-catenin by double-stranded RNA
6 Apr 20
This invention relates to compounds, compositions, and methods useful for reducing β-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 8 Jul 18
Utility
Ligand-modified Double-stranded Nucleic Acids
29 Jan 20
The invention provides for double stranded nucleic acid molecules comprising a 5′ extension of the sense or antisense strand and further comprising a plurality of nucleotides that are conjugated to a ligand and methods of using the double-stranded nucleic acid molecules.
Bob Dale Brown, Weimin Wang
Filed: 28 Aug 19
Utility
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-stranded Rna
1 Jan 20
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 19 Aug 19
Utility
Methods and Compositions for the Specific Inhibition of APLHA-1 Antitrypsin by Double-stranded Rna
25 Dec 19
This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 27 Jun 19
Utility
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
25 Nov 19
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 7 Mar 19
Utility
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
4 Nov 19
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 7 Mar 19
Utility
Therapeutic Inhibition of Lactate Dehydrogenase and Agents Therefor
23 Oct 19
This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek, Cheng Lai
Filed: 14 Mar 19
Utility
Double-stranded Nucleic Acid Inhibitor Molecules Modified with Tm-increasing Nucleotides
16 Oct 19
Provided herein are double-stranded nucleic acid inhibitor molecules having a sense strand with a stem loop structure and an antisense strand, where the stem portion of the stem loop structure contains one or more Tm-increasing nucleotides.
Weimin Wang, Naim Nazef, Bob Dale Brown
Filed: 10 Apr 19
Utility
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
7 Oct 19
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 24 Oct 17